Aarey Drugs & Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.99×	0.73×	0.66×	0.88×	0.66×
	1.17×	1.25×	19.91×	1.94×	0.91×
	0.9%	0.9%	0.1%	0.7%	1.3%
	1.76×	1.76×	1.74×	1.33×	0.23×
	1.98×	1.98×	1.72×	2.30×	2.48×
	3.5%	2.9%	2.5%	3.6%	0.5%
	2.8%	2.8%	3.0%	3.7%	0.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

AAREYDRUGS₹110.84

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersNECLIFE NATCAPSUQ MEDICAMEQ MEDICO BALPHARMA ALPA KREBSBIO HALEOSLABSMcap ₹315 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.66	0.88	0.66	0.73	0.99
Interest Burden (Pretax/EBIT) ×	0.91	1.94	19.91	1.25	1.17
EBIT Margin %	1.31	0.70	0.06	0.91	0.86
Asset Turnover ×	0.23	1.33	1.74	1.76	1.76
Financial Leverage (Assets/Equity) ×	2.48	2.30	1.72	1.98	1.98
ROE (5-step product, year-end total equity) %	0.45	3.62	2.54	2.92	3.50
ROE (owners' profit / average owners' equity) %	0.43	3.74	2.97	2.75	2.75

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.